Navigation Links
Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
Date:8/21/2008

com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before FDA can be applied for and the FDA may not approve the pandemic vaccine even if further trial results are similar to those disclosed herein; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
2. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
3. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
4. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
7. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
8. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
9. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
10. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014  Major advances in radiation therapy and ... highlighted in a three-day Oncology Summit taking place ... 2014.  Renowned national and international cancer experts from seven ... exchange knowledge on modern technologies making treatment for ... The Summit will address a wide ...
(Date:7/10/2014)...  The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. ... a unique model developed at UH to enhance care ... or demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... Calif. , July 10, 2014 Integrated ... leader in advanced memory and analog IC solutions, today ... on Thursday, July 24, 2014, at 7:00 a.m. Pacific ... financial results for the fiscal 2014 third quarter ended ... call via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... health has won out over the actions of a ... Jane L. Delgado, President and CEO of the National ... Hispanic health advocacy group. Commenting on actions taken by ... the Federal Trade Commission (FTC) to halt fraudulent claims, ...
... MiMedx Group, Inc. (OTCBB: MDXG), an integrated ... products and bioimplants processed from human amniotic membrane, ... the Company,s latest biologic implant processed to offer ... Produced from the MiMedx Group,s proprietary Purion® ...
Cached Medicine Technology:FDA Moves to Stop Bogus Products Sold Over the Counter and Online that Falsely Claim to Cure and Treat STDs 2MiMedx Announces Launch of AmnioFix™ Nerve Wrap 2
(Date:7/11/2014)... Datalogic brings a new and innovative ... wide. With their new Gryphon GD4400 and ... the devastating MRSA, which claimed 5,500 lives, becomes more ... 2D and the Gryphon GM4400-HC 2D readers can scan ... read barcodes off of troublesome LCD monitors, smartphones, and ...
(Date:7/11/2014)... -- Children who have emergency surgery on weekends ... even death than those who have weekday surgeries, ... Johns Hopkins researchers noted that the risk of ... on nearly 440,000 simple emergency surgeries that children ... period. The surgeries are considered generally safe ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, ... exclusively to cell and gene therapies for cancer ... the organization as Senior Development Officer. , Corday ... securing gifts and addressing influential donors. Prior to ... for NewYork Presbyterian Hospital/Columbia University Medical Center, where ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Presently, disposable ... overall healthcare equipment and supplies segment. During the past ... witnessed steady growth (on an average 12.5% per year), ... healthcare settings. Currently, the US is the largest market ... a share of 40%. The second position is held ...
(Date:7/11/2014)... Wash.The largest study of its kind has found ... of advantages over their conventional counterparts, including more ... The study looked at an unprecedented 343 peer-reviewed ... organic and conventional plant-based foods, including fruits, vegetables, ... techniques to quantify differences between organic and non-organic ...
Breaking Medicine News(10 mins):Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3
... PLoS Medicine is Open Access: freely available for ... as long as the authorship is properly attributed. ... collection of articles that aim to highlight the ... of the Council of Science Editors Global Theme ...
... real Mutter Museum ... PHILADELPHIA, Oct. 22 The skulls in the glass case ... malformed body parts. The,background noise is filled with gasps from ... day at the Mutter Museum. Ever,wonder what the museum does ...
... Howard Dean issued the following statement in response,to President ... billion,in war spending, for a total of $196 billion, ... to 10 million of America,s low income children:, ... fund his war of,choice in Iraq but has no ...
... reports in this weeks issue of the Proceedings of the ... the damaging effects of ultraviolet (UV) radiation the most ... of an extract of broccoli sprouts. , The results ... show that the degree of skin redness (erythema) caused by ...
... of $59.1 million, or 61 cents per share. ... 400 basis point year-over-year improvement in quarterly Fine ... Chemicals segment income margin., RICHMOND, Va., Oct. 22 ... of $59.1 million, or 61,cents per share, up from $2.3 million, or ...
... Inc.,(Nasdaq: ATRC ), a medical device company focused ... release,its financial results for the quarter ended September 30, ... a conference call at 10:00 am ET on Tuesday,November ... live web cast of,the conference call will be available ...
Cached Medicine News:Health News:Which intervention would do the most to improve the health of the extreme poor? 2Health News:Which intervention would do the most to improve the health of the extreme poor? 3Health News:Which intervention would do the most to improve the health of the extreme poor? 4Health News:Which intervention would do the most to improve the health of the extreme poor? 5Health News:Halloween at The Mutter Museum 2Health News:Broccoli sprout-derived extract protects against ultraviolet radiation 2Health News:Albemarle Reports Third Quarter 2007 Results 2Health News:Albemarle Reports Third Quarter 2007 Results 3Health News:Albemarle Reports Third Quarter 2007 Results 4Health News:Albemarle Reports Third Quarter 2007 Results 5Health News:Albemarle Reports Third Quarter 2007 Results 6Health News:Albemarle Reports Third Quarter 2007 Results 7Health News:Albemarle Reports Third Quarter 2007 Results 8Health News:Albemarle Reports Third Quarter 2007 Results 9Health News:Albemarle Reports Third Quarter 2007 Results 10Health News:AtriCure Announces Web Cast and Conference Call of Third Quarter 2007 Financial Results 2
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... The Carpal Solution offers relief from CTS ... is different from other over-the-counter CTS treatments. ... Worn during sleep, the Carpal Solution gently ... Carpal Tunnel and eliminates hand pain, numbness ...
... Linearity is a whole blood formulation ... range of the most popular glucose ... of using a control matrix that ... is packaged in ready-to-use dropper vials ...
... ESR-10 Manual Rack is a manual ... the erythrocyte sedimentation rate (ESR) of ... 1.2ml Streck ESR-Vacuum Tubes. The rack ... simultaneously. The ESR-10 Manual Rack exhibits ...
Medicine Products: